atai Life Sciences (NASDAQ: ATAI) has made a play to bolster their psychedelics portfolio. The company announced a strategic investment in Beckley Psytech Limited, a
While psychedelic trials continue to amass promising data on the clinical side, an important event has taken place as it relates to reimbursement. The American
atai Life Sciences (NASDAQ: ATAI), the tier-1 biopharmaceutical trialing psychedelic compounds for the treatment of mental health disorders, has unveiled positive findings from its Phase
Awakn Life Sciences (NEO: AWKN, OTCQB: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has entered into a global
In a recent podcast interview, Robert F. Kennedy Jr. shared his perspectives on the potential of psychedelics as a mental health treatment. This revelation coincides
Sunstone Therapies announced full results and methodology for its phase 2 clinical trial of psilocybin-assisted therapy to treat cancer patients suffering from major depressive disorder.
Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of December 11. Aside from presenting a synopsis of events, we provide
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company dedicated to pioneering innovative treatments for brain health disorders, has announced topline outcomes
The moment that many psychedelic participants and investors have waited for has finally arrived. Today, MAPS Public Benefit Corporation (MAPS PBC) has formally communicated the
Australian researchers have analyzed the genetic makeup of over 100 strains of Psilocybe cubensis, a psychoactive mushroom commonly known as the magic mushroom, encompassing both